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Abstract
Background: A systematic review is made to determine whether human immunodeficiency virus (HIV) infection 
has an impact upon dental implant osseointegration.
Material and Methods: A PubMed (MEDLINE) literature search was made of articles published up until 14 April 
2014. The systematic review was conducted based on the Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA). The quality of the studies included in the review was assessed using the Methodological 
Index for Nonrandomized Studies (MINORS) and levels of evidence (based on the University of Oxford’s Center 
for Evidence Based Medicine criteria).
Results: The combinations of search terms resulted in a list of 132 titles. Nine studies finally met the inclusion 
criteria and were selected for inclusion in the systematic review. A total of 173 dental implants were placed in 80 
patients (135 implants in 56 HIV-positive subjects and 38 implants in 24 HIV-negative patients), and a single loss 
of dental implant osseointegration was recorded in an HIV-positive patient.
Conclusions: Our results suggest that dental implant placement in HIV-positive patients does not increase the 
dental implant failure rate. Prophylactic antibiotic treatment, the administration of highly active antiretroviral 
therapy, and control of the CD4+ T lymphocyte counts appear to be the main influencing factors in this respect. 
Given the few studies included in our systematic review, further prospective studies involving larger sample sizes 
and longer durations of follow-up are required in order to confirm the results obtained.
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Introduction
Human immunodeficiency virus (HIV) infection is a 
major public health problem. According to estimations 
of the United Nations, 34 million people throughout the 
world suffer from HIV/Acquired Immune Deficiency 
Syndrome (AIDS) (1).
The disease is characterized by progressive immune 
system failure that gives rise to the development of op-
portunistic infections and neoplasms. The virus inva-
des CD4+ T lymphocytes, macrophages and dendritic 
cells, and the CD4+ T cell counts gradually decrease as 
a result of direct cytopathic action or cytotoxic CD8+T 
lymphocyte-mediated attack. Cellular immunity is 
affected once the lymphocyte count has dropped to be-
low a critical point, and the patient becomes vulnerable 
to opportunistic infections. On the other hand, if HIV 
viral replication is not inhibited, the resulting immune 
activation increases the risk of cardiovascular events, 
tumors and kidney, liver and neurological disorders, 
among other problems (2-4). Following the introduc-
tion of highly active antiretroviral therapy (HAART) 
in 1996, the mortality rates associated with AIDS have 
decreased drastically, and enormous benefits have been 
obtained in terms of lessened patient morbidity and 
transmission of the infection. At present, thanks to the 
availability of increasingly effective and better tolerated 
antiretroviral treatments, the disease has been brought 
under control and the epidemic has been stabilized. 
This situation in turn has generated new challenges, for 
although HIV-infected individuals undergoing elective 
procedures and treatments have an adequate immune 
status, there are a number of factors that distinguish 
them from the general population, such as age (75% of 
the HIV-positive population is over 40 years of age), 
an increased prevalence of comorbidities, long-term 
complications of HAART, a greater need for medical 
care, the need for regular medication, and chronic in-
flammation (4-8). In this respect, it would be interesting 
to determine whether the dental implant osseointegra-
tion and success rates in HIV-infected individuals are 
the same as that observed in the general population. It 
should be taken into account that bone metabolic altera-
tions are frequent in the context of HIV infection, due 
to a number of factors such as physical inactivity, de-
pression, smoking, alcohol and opiate abuse, low testos-
terone levels, suboptimum calcium / vitamin D intake, 
and HAART (9).
A number of studies (10,11) have explored the association 
between different local and systemic factors and dental 
implant osseointegration. Buser et al. (11), on occasion of 
the second international team of oral implantology (ITI) 
consensus conference, proposed dividing the systemic 
risk factors affecting dental implant osseointegration 
into two groups: very high risk and significant risk. They 
concluded that immune depressed individuals, whether 
infected by HIV or subjected to immunosuppressive 
treatment (such as transplant patients), are at high risk.
Few data are found in the literature on dental procedures 
and their complications in HIV-infected patients, and 
there is limited experimental and clinical experience 
with dental implant placement in HIV infection. The 
present systematic review was therefore carried out to 
determine whether HIV infection has an impact upon 
dental implant osseointegration.
Material and Methods
The Preferred Reporting Items for Systematic Reviews 
and Meta-analysis (PRISMA) statement was used in 
this study (12).
- PICO question
Does HIV infection have an impact upon dental implant 
osseointegration?
Search strategy for the identification of studies
The PubMed (MEDLINE) database of the United 
States National Library of Medicine was used for a 
literature search of articles published up until 14 April 
2014. The following search terms were used in different 
combinations: “dental implant”, “AIDS”, “HIV”, “HIV-
positive”, “HAART”, “HAART HIV”. Two examiners 
read the titles and abstracts of all studies, and no blinding 
was carried out regarding author names, journals or 
publication date. The search was completed with a 
review of the references of the selected articles in order 
to identify additional studies not found in the initial 
literature search.
In addition, a manual search (up until 14 April 2014) 
was made of the following journals: Clinical Implant 
Dentistry and Related Research, Clinical Oral 
Investigations, Clinical Oral Implants Research, Implant 
Dentistry, International Journal of Oral and Maxillofacial 
Implants, Journal of Clinical Periodontology, Journal of 
Oral Implantology, Journal of Oral and Maxillofacial 
Surgery, Journal of Periodontology, Medicina Oral, 
Patologıa Oral y Cirugıa Bucal, and Oral Surgery and 
Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontology.
- Study selection criteria
Before starting the study, a series of inclusion and 
exclusion criteria were established. Chosen full-text 
articles were assessed for the following inclusion 
criteria: (a) Studies including HIV-infected patients 
receiving at least one dental implant; (b) Prospective 
and retrospective studies, case series and case reports. 
In vitro or animal studies were excluded. Authors were 
contacted for clarification of missing information when 
necessary. No restrictions were placed on the year or 
language of publication. All articles selected from the 
electronic and manual searches were independently 
assessed by the first and second authors of the present 
study, according to the established inclusion criteria. 
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Any disagreements between the reviewing authors were 
resolved by consensus, or by consulting the last signing 
author of the study.
- Quality assessment
Two authors independently evaluated the quality of 
the studies included in the systematic review using 
the Methodological Index for Nonrandomized Studies 
(MINORS) (13). The MINORS scale includes the 
following points: (a) a clearly stated aim; (b) inclusion of 
consecutive patients; (c) prospective collection of data; 
(d) appropriate endpoints; (e) unbiased assessment; (f) a 
follow-up period; (g) losses to follow-up of < 5%; and 
(h) prospective calculation of the study size for non-
comparative studies (Table 1), and additional criteria 
in the case of comparative studies; (i) an adequate 
control group; (j) contemporary groups; (k) baseline 
equivalence of groups; and (l) adequate statistical 
analyses (Table 2). The items on the MINORS scale are 
scored as 0 (not reported), 1 (reported but inadequate) 
or 2 (reported and adequate). The ideal global score is 
16 for non-comparative studies and 24 for comparative 
studies. Furthermore, we defined study quality as 
poor (< 5), fair (6-10) or good (> 11). Quality was also 
assessed according to the levels of evidence (based on 
the University of Oxford’s Center for Evidence Based 
Medicine criteria) (23) (Tables 1 and 2).
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Results
- Study selection
The combinations of search terms resulted in a list of 
132 titles. Of these, 22 were found to be duplicated; as 
a result, 110 references were reviewed. Subsequently, 
101 papers were excluded on the basis of the evaluation 
of the title and abstract, thus leaving 9 articles for 
eligibility assessment. Nine publications finally met the 
inclusion criteria and were thus selected for inclusion in 
the systematic review (Fig. 1).
- Assessment of study quality
Two reviewers (JAA and FAA) independently and in 
duplicate evaluated the quality of the included studies as 
part of the data extraction process. Any disagreements 
were resolved by consensus or by consulting the last 
signing author of the present study. The mean score 
for all case series was 9, with a range of 8-10. The 
mean score for all case reports was 6.5, with a range 
of 6-7. This suggests fair quality of the included non-
comparative studies. The mean score for all prospective 
studies was 19.5, with a range of 17-22, which suggests 
good quality of the included comparative studies. In the 
level of evidence assessment, 7 studies (14-20) ranked 
as level 4, one study (21) corresponded to level 2b, and 
one study (22) was ranked as level 1b.
- Description of the studies
Of the 9 studies included in the systematic review, 
four were case reports (14-17), three were case series 
(18-20), and two were prospective studies (21,22). 
The demographic data (patient age and sex) and 
information referred to the dental implants (number 
and type, failed implants, location and follow-up) of the 
publications are summarized in table 3. The laboratory 
test data (CD4+ T lymphocyte count and viral load) 
and information referred to antiretroviral therapy and 
preventive treatment in turn are summarized in table 
4. In the present systematic review, a total of 173 dental 
implants were placed in 80 patients (135 implants in 
56 HIV-positive subjects and 38 implants in 24 HIV-
negative patients belonging to the control groups of 
the prospective studies) (21,22). A single loss of dental 
implant osseointegration was recorded in an HIV-
positive patient.
Discussion
The present systematic review has examined the 
scientific evidence with a view to determining the 
possible impact of HIV infection upon dental implant 
osseointegration. We analyzed a total of 9 studies in 
which 173 implants were placed, and only one implant 
osseointegration failure was recorded, corresponding to 
an HIV-infected individual.
Since the introduction of HAART in 1996, survival 
among HIV-infected individuals has greatly improved, 
and new challenges have appeared. In this respect, 
dental implant placement in HIV-infected patients 
is increasingly common, though the impact of HIV 
infection upon the success of implant osseointegration 
has not been fully established. The studies published 
to date (24,25) have not found major surgery to have 
a negative impact upon patients with HIV infection. 
Studies conducted in the early post-HAART era (24,25) 
have shown the evolution of CD4+ T cell counts in 
surgical patients to be similar to that seen in individuals 
not subjected to surgery. However, although surgery 
does not influence the evolution of HIV infection, 
Study
Stevenson et al. 
2007 (21)
Oliveira et al. 
2011 (22)
Clear aim (a) 2 2 
Inclusion of consecutive patients (b) 2 2 
Prospective collection data (c)  2 2 
Appropriate endpoints (d) 2 2 
Unbiased assessment (e) 0 0 
Follow-up period (f) 2 2 
Losses to follow-up less than 5% (g) 1 2 
Prospective calculation of the study size (h) 0 2 
Adequate control group (i) 2 2 
Contemporary groups (j) 2 2 
Baseline equivalence of groups (k) 2 2 
Adequate statistical analyses (l) 0 2 
Total score (of 24) 17 22 
Study quality Good Good 
Levels of evidence (CEMB 2011) 2b 1b 
Table 2. Quality assessment scores of prospective studies using the 12-point MINORS scale and 
levels of evidence (CEMB 2011).
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the latter might influence the outcome of surgery. In 
this regard, conflicting results have been obtained by 
studies that have examined the effect of HIV infection 
upon the success and tolerance of surgery (26-34). Some 
articles, mostly published in the pre- or early post-
HAART era (26-31), have described more postoperative 
complications in HIV-infected individuals than in 
the general population. The most frequently reported 
problems have been bacterial infections, with CD4+ T 
lymphocyte count and viral burden as underlying risk 
factors. However, some recent studies (32-34) on the 
efficacy and tolerability of different surgical procedures 
in HIV-infected patients have recorded data similar to 
those found in the general population.
The natural history of HIV infection has changed 
drastically since the introduction of HAART. In 
effect, the availability of effective and well tolerated 
antiretroviral treatments has led to a notorious increase 
in patient survival, with a lesser incidence of AIDS-
defining diseases. Furthermore, the causes of death 
have changed, and the associated chronic disorders 
have grown in importance (8).
In the HIV-positive population, bone metabolic disorders 
have become common as a result of the improvements 
in life expectancy. The most frequently reported 
bone disorders in these subjects are related to bone 
demineralization, such as osteoporosis and osteopenia 
(9,35,36). A study in HIV-infected patients has recorded 
prevalences of osteopenia and osteoporosis of 48% and 
23%, respectively (37). Osteoporosis is characterized 
by a decrease in bone density and mineral content in 
peripheral bone, associated to increased maxillary 
resorption and atrophy. However, there is no associated 
increase in dental implant loss (38). A study involving 
the placement of 82 dental implants in 39 patients 
(including 39 implants in 19 osteoporotic patients) 
recorded no statistically significant differences between 
the patients with osteoporosis and those without – the 
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Fig. 1. Prisma® flow diagram of the search processes and results.
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Study data Demographic data Implant data 
Article Type of study 
Age
(years) 
Sex 
(M/F) 
No. placed 
implants/no.
failed
implants
Location Follow-up period Type of implant 
Romanos
et al. 2014 Case report         43     M       16/0 
6 post, max 
2 ant, max 
6 post, mand 
2 ant, mand 
Every 3 
months
during 24 
months
(Ankylos; Dentsply Implants, 
Waltham, 
MA) 
Oliveira et 
al. 2011 Prospective
Mean test 
group 1: 
46.9 
9M/2F 20/0 20 post 12 months (Implus implants, Serson Implant, São Paulo) 
Mean test 
group 2: 
45.9 
10M/3F 19/0 19 post 12 months (Implus implants, Serson Implant, São Paulo) 
Mean 
control
group: 45.8 
7M/8F 20/0 20 post 12 months (Implus implants, Serson Implant, São Paulo) 
Kolhatkar
et al. 2011 Case series 
55 M 1/0 1 post, mand 
After 2 
weeks and 1 
month
(Zimmer Dental, Carlsbad, 
CA)
48 M 2/0 2 post, mand 
After 2 
weeks and 1 
month
(BIOMET 3i, Palm Beach 
Gardens, FL) 
Stevenson 
et al. 2007 Prospective
Mean test 
group: 48.9 
Test 
group:
14M/6F
40/0 40 ant, mand 6 months (BioHorizons dental system, Inc., Birmingham, AL) 
Mean 
control
group: 65.3 
Control
group:
3M/6F
18/0 18 ant, mand 6 months (BioHorizons dental system, Inc., Birmingham, AL) 
Strietzel et 
al. 2006 Case series 
64 M 4/1 4 ant, mand 30 months 
(4 Frialit – 2 Screw-type 
implants, DenstplayFriadent, 
Mannheim, Germany) 
38 M 2/0 2 post, mand 28 months (Single Frialit 2 Screw-type implant) 
49 F 4/0 4 ant, mand 25 months 
(4 Frialit – 2 Screw-type 
implants, DenstplayFriadent, 
Mannheim, Germany) 
Achong et 
al. 2006 Case series 
56 M 2/0 2 post, mand 24 months (Zimmer Dental, Carlsbad, CA)
45 M 2/0 2 post, mand 24 months (Zimmer Dental, Carlsbad, CA)
46 M 2/0 2 ant, mand 12 months (Zimmer Dental, Carlsbad, CA)
Shetty and 
Achong
2005
Case report 47 M 8/0 5 post, max 3 post, mand 36 months Not specified 
Baron et 
al. 2004 Case report 27 F 12/0 
4 post, max 
2 ant, max 
6 post, mand 
24 months 
(Branemark implants 
Nobel Biocare, Göteborg, 
Sweden) 
Rajnay and 
Hochstetter 
1998
Case report 38 M 1/0 1 ant, mand 18 months (Micro-Miniplant, Implant Innovations, Inc.) 
Table 3. Demographic and dental implant data of the studies included in the systematic review.
Nº= number  M = Male   F = Female    Post = Posterior  Ant = Anterior   Max = Maxilla Mand = Mandible.
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 Laboratory data Treatment data 
Article CD4+(cells/ml) 
Viral load 
(copies/ml) Antiretroviral therapy Preventive treatment 
Romanos et al. 
2014
479 Not specified Antiretroviral therapy (Atripla, 
Bristol- 
Myers Squibb and Gilead Sciences, 
Foster City, CA) 
Penicillin 2 g 1 hour before surgery 
and 500 mg 3 times/day x 1 week 
Oliveira et al. 
2011 
Mean: 400 Mean: <50 PI-based HAART Amoxicillin 500 mg 3 times/day x 5 
days; piroxicam 20 mg once a day x 
3 days 
Mean: 543.5 Mean: <50 NNRTI-based HAART (without PI) Amoxicillin 500 mg 3 times/day x 5 
days; piroxicam 20 mg once a day x 
3 days 
Control group. 
HIV-negative 
patients 
Control group. 
HIV-negative 
patients 
Control group. HIV-negative patients Amoxicillin 500 mg 3 times/day x 5 
days; piroxicam 20 mg once a day x 
3 days 
Kolhatkar et 
al. 2011 
344 57 Atazanavir sulfate, ritonavir, 
emtricitabine, 
and tenofovir disoproxil fumarate 
Ibuprofen 600 mg before surgery and 
azithromycin 250-mg (two tablets at 
start and 250 mg on days 2 to 5); 800 
mg ibuprofen (1 tablet 3 times/day as 
needed for pain) and rinses 0.12% 
CLX
379 32.551** Raltegravir, 
ritonavir, darunavir, and maraviroc 
Azithromycin and rinses 0.12% CLX 
Stevenson et 
al. 2007 
Mean test 
group: 505.3 
Mean test group: 
11682.6 
 Amoxicillin 1 hour before surgery 
and for 7 days after. CLX rinses 
Control group. 
HIV-negative 
patients 
Control group. 
HIV-negative 
patients 
Control group. HIV-negative patients Amoxicillin 1 hour before surgery 
and for 7 days after. CLX rinses 
Strietzel et al. 
2006
408* <50 Nevirapine, ritonavir, didanosine and 
saquinavir 
Ibuprofen 600 mg 3 times/day for 
postoperative pain control. 0.12% 
CLX rinses 
800* <50 Lamivudine/zidovudine and abacavir Ibuprofen 600 mg 3 times/day for 
postoperative pain control. 0.12% 
CLX rinses 
576* <50 Lopinavir, lamivudine, and abacavir Ibuprofen 600 mg 3 times/day for 
postoperative pain control. 0.12% 
CLX rinses 
Achong et al. 
2006
Before surgery: 
180*
1 week after 
surgery: 250* 
8000 Nevirapine, lopinavir/ritonavir and 
abacavir 
sulfamethoxazole-trimethoprim, 
cephalexin 500 mg 4 times/day x 1 
week and 0.12% CLX rinses 
Before surgery: 
202*
1 week after 
surgery: 468* 
4500 Lamivudine, nevirapine and 
lopinavir/ritonavir 
Cephalexin 500 mg 4 times/day x 1 
week and 0.12% CLX rinses 
Before surgery: 
431*
1 week after 
surgery: 657* 
9200 Lamivudine/zidovudine and 
lopinavir/ritonavir 
Cephalexin 500 mg 4 times/day x 1 
week and 0.12% CLX rinses 
Shetty and 
Achong 2005 
Before surgery: 
175*
1 week after 
surgery: 215* 
Undetectable Nevirapine, ritonavir and abacavir 500 mg cephalexin 4 times/day x 1 
week and 0.12% CLX rinses 
Baron et al. 
2004
396* <50 400 mg didanosine, 80 mg stavudine, 
600 mg efavirenz and 300 g 
lamivudine
Tramadol hydrochloride 900 mg/day, 
clindamycin 
Rajnay and 
Hochstetter 
1998
150-200 600-35000 NRTIs at the time of implant surgery. 
Switch 6 months after surgery to a 3-
drug regimen that included a PI 
800 mg ibuprofen, 500 mg 
amoxicillin 7 days and CLX rinses 
Table 4. Laboratory test and treatment data of the studies included in the systematic review.
*cells/µl; CLX = chlorhexidine; HAART= highly active antiretroviral therapy NRTIs = nucleoside analog reverse-transcriptase inhibitors 
**copies/µl; NNRTIs: non-nucleoside reverse transcriptase inhibitors PI: protease inhibitor.
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dental implant success rate being 98.8% (39). In a 
retrospective study of 70 dental implants in osteoporotic 
patients, the implant success rate was found to be 97% 
after over three years of follow-up (40).
A number of factors might contribute to the high 
prevalence of such bone metabolic disorders in HIV-
infected patients. In this respect, it is possible that 
no single factor can explain the development of these 
disorders; rather, the underlying cause may be a 
combination of factors that are characteristically more 
prevalent in such individuals, such as low body weight, 
malnutrition, malabsorption, suboptimum calcium / 
vitamin D intake, physical inactivity, low testosterone 
levels, smoking, alcohol and other substance abuse, 
HIV disease itself, and HAART (9). The proposed 
mechanisms whereby the virus could contribute to the 
loss of bone mineral density are related to osteoclast 
stimulation and diminished bone production on the 
part of the osteoblasts. The stimulation of osteoclast 
activity would be a response to the increased production 
of proinflammatory cytokines secondary to chronic T 
cell activation, while diminished bone production on 
the part of the osteoblasts would be a consequence of 
increased apoptosis among these cells (41-43). Certain 
drugs, such as the bisphosphonates, significantly reduce 
bone turnover. It is therefore not surprising that a patient 
taking bisphosphonates may have a problem with dental 
implant integration (44), with the associated risk of 
osteonecrosis of the jaws (45). However, several studies 
(46-48) have shown the dental implant failure rate in 
patients who receive these drugs to be similar to that 
seen in patients who do not receive such treatments.
In a study of 40 dental implants placed in 20 HIV-
infected patients, no implant osseointegration failures 
were recorded after 6 months of follow-up (21). Likewise, 
in another study of 39 dental implants placed in 24 HIV-
infected patients, no implant osseointegration failures 
were recorded after one year of follow-up (22). The above 
findings have been corroborated by several studies (14-
18,20) in HIV-infected individuals in which no dental 
implant osseointegration failures were observed. Of the 
173 dental implants included in our systematic review, 
only one osseointegration failure was documented, 
corresponding to an implant placed in the lower anterior 
sector in a woman, after 30 months of follow-up (19).
It is logical to assume that antibiotic use is indicated 
in HIV-negative patients, as has been demonstrated in 
a meta-analysis in which antibiotic use significantly 
lowered the implant failure rate (p = 0.003), with an odds 
ratio of 0.331 - thus implying that antibiotic treatment 
reduced the odds of implant failure by 66.9% (49). It 
therefore can be postulated that antibiotics should also 
be prescribed in HIV-positive individuals in order both 
to reduce implant failure and to minimize the risk of 
postoperative infections.
- Study limitations
The main limitation of this systematic review is 
the small number of articles that were available for 
evaluation. Our aim was to conduct a meta-analysis 
to determine whether human immunodeficiency virus 
(HIV) infection has an impact upon dental implant 
osseointegration. This was not possible mainly because 
of the heterogeneity of the studies in relation to the types 
of implants used, and the differences in antiretroviral 
therapy, preventive treatment (antibiotics and analgesics), 
and follow-up periods. Another limitation is the fact 
that our systematic review included publications with 
a lower level of evidence than randomized controlled 
trials (RCTs). The absence of randomized controlled 
trials therefore means that our review is based on rather 
limited evidence.
Conclusions
Based on the results of our systematic review of 
the literature, it seems that the prognosis of dental 
implant placement in HIV-infected patients is good 
and similar to that seen in HIV-negative individuals. 
This is particularly manifest in the presence of 
HAART, controlled CD4+ T lymphocyte counts, and 
the administration of prophylactic antibiotic therapy. 
However, further prospective studies involving larger 
sample sizes and longer durations of follow-up are 
required in order to confirm the results obtained.
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